Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review

BMC Medical Research Methodology

Volumn 13, Issue 1, 2013, Pages

  Boussageon, Rémy ^a   Supper, Irène ^a   Erpeldinger, Sylvie ^a   Cucherat, Michel ^a   Bejan Angoulvant, Theodora ^b,c   Kassai, Behrouz ^a,d   Cornu, Catherine ^a,d   Gueyffier, François ^a,d  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d LOUIS PRADEL HOSPITAL   (France)

Author keywords

Blood glucose; Concomitant treatment; Observer bias; Randomized controlled trial; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; GLUCOSE BLOOD LEVEL;

BLOOD; DIABETES MELLITUS; EPIDEMIOLOGY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVER VARIATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2;

ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; OBSERVER VARIATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84883563708     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-13-107     Document Type: Article

References (36)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998 352 837 853 9742976
2. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association, Diabetes Care 2009 32 193 203 10.2337/dc08-9025 18945920
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998 352 854 865 9742977
4. Some answers, more controversy, from UKPDS. Nathan DM, Lancet 1998 352 832 833 9742972 (Pubitemid 28416714)
5. The case against agressive treatment of type 2 diabetes: critique of the UK prospective diabetes study. Ewart RM, BMJ 2001 323 854 858 10.1136/bmj.323.7317.854 11597972
6. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. McCormack J, Greenlahg T, BMJ 2000 320 1720 1723 10.1136/bmj.320.7251.1720 10864554 (Pubitemid 30410489)
7. Blinding in randomised trials: hiding who got what. Schulz KF, Grimes DA, Lancet 2002 359 696 700 10.1016/S0140-6736(02)07816-9 11879884 (Pubitemid 34203775)
8. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators, Lancet 2005 366 1849 1861 16310551
9. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, D'Emden MC, Crimet DC, O'Connell RL, Colman PG, FIELD study investigators, Lancet 2007 370 1687 1697 10.1016/S0140-6736(07)61607-9 17988728 (Pubitemid 350100775)
10. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group, BMJ 1998 317 703 713 10.1136/bmj.317.7160.703 9732337
11. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators, Lancet 2000 355 253 259 10675071
12. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group, Lancet 2004 363 757 767 15016485
13. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American diabetes association, a scientific statement of the American heart association, and an expert consensus document of the American college of cardiology foundation. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS, American Diabetes Association, Diabetes Care 2010 33 1395 1402 10.2337/dc10-0555 20508233
14. Effect of intensive glucose-lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes mellitus: a meta-analysis of randomised controlled trials. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C, BMJ 2011 343 4169 10.1136/bmj.d4169 21791495
15. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. UGDP, Diabetes 1982 31 1 81 10.2337/diabetes.31.1.1 6757026
16. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6 year study. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M, Diab Res Clin Pract 1995 28 103 117 10.1016/0168-8227(95)01064-K
17. Cardiovascular events and correlates in veterans affairs diabetes feasibility trial. Veterans affairs cooperative study on glycemic control and complications in type II diabetes. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, Emanuele NV, Levin SR, Pacold I, Lee HS, Arch Intern Med 1997 157 181 188 10.1001/archinte.1997.00440230053007 9009975 (Pubitemid 27058152)
18. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group, N Engl J Med 2008 358 2560 2572 18539916
19. Effects of intensive glucose lowering in type 2 diabetes. The ACCORD study group, N Engl J Med 2008 358 2545 2559 18539917
20. Glucose control and vascular complications in veterans with type 2 diabetes. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators, N Engl J Med 2009 360 129 139 10.1056/NEJMoa0808431 19092145
21. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Shichiri M, Kishikawa H, Ohkubo Y, Wake N, Diabetes Care 2000 23 21 B29 10860187
22. How should Meta-regression analyses be undertaken and interpreted? Thompson SG, Higgins JP, Stat Med 2002 21 1559 1573 10.1002/sim.1187 12111920 (Pubitemid 34746063)
23. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-protect 2): a randomised placebo-controlled trial. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N, DIRECT Programme Study Group, Lancet 2008 372 1385 1393 10.1016/S0140-6736(08)61411-7 18823658
24. Renal and retinal effects of enalapril and losartan in type 1 diabetes. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R, N Engl J Med 2009 361 40 51 10.1056/NEJMoa0808400 19571282
25. Effects of medical therapies on retinopathy progression in type 2 diabetes. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ, ACCORD Study Group, N Engl J Med 2010 363 233 244 Erratum in: N Engl J Med 2011, 364: 190 20587587
26. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Lamanna C, Monami M, Marchionni N, Mannucci E, Diabetes Obes Metab 2011 13 221 228 10.1111/j.1463-1326.2010.01349.x 21205121
27. Follow-up of intensive glucose control in type 2 diabetes. Mühlhauser I, N Engl J Med 2009 360 417 19172674
28. Follow-up of intensive glucose control in type 2 diabetes. The authors reply. Holman RR, Matthews DR, Neil HA, N Engl J Med 2009 360 418 19164196
29. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Schulz KF, Chalmers I, Hayes RJ, Altman DG, JAMA 1995 273 408 412 10.1001/jama.1995. 03520290060030 7823387
30. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP, Lancet 1998 352 609 613 10.1016/S0140-6736(98)01085-X 9746022 (Pubitemid 28380142)
31. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA, BMJ 2008 336 601 605 Epub 2008 Mar 3 10.1136/bmj.39465.451748.AD 18316340 (Pubitemid 351439518)
32. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Trial Research Group, JAMA 1982 248 1465 1477 7050440
33. Hyperglycaemia as a cardiovascular risk factor in diabetes. Yudkin J, BMJ 2008 372 1036 1037
34. The Hawthorne studies-a fable for our time? Gale EAM, QJM 2004 97 439 449 10.1093/qjmed/hch070 15208432 (Pubitemid 38967418)
35. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Schulz KF, Altman DG, Moher D, CONSORT Group, BMJ 2010 340 332 10.1136/bmj.c332 20332509
36. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Moher D, Schulz KF, Altman DG, Lancet 2001 357 1191 1194 10.1016/S0140-6736(00)04337-3 11323066 (Pubitemid 32378696)